The European ablation devices market is estimated to be worth USD 4.64 billion by 2027 from USD 2.71 billion in 2022, growing at a CAGR of 11.36% from 2022 to 2027.
The growing number of patients with cancer and heart-related problems in the European population is driving the growth of European ablation devices. As per the data published by the European Commission, an estimated 4 million new cancer cases were found in Europe in 2020, and an estimated 1.9 million people died of cancer. These cancer patients prefer ablation treatment to kill tumor cells, which helps impede the further growth of the cancer cells in the body, supporting a healthy life.
In addition, the increasing geriatric population in the European region is promoting the growth rate of the European ablation devices market. According to Eurostat, an estimated 31.3% of the European population is expected to be more than 65 years by 2100, which was 20.8% in 2021. The growing preference for minimally invasive surgeries in the European region is expected to fuel the growth rate of the European market. Ablation devices provide minimal invasion surgeries to kill tumor cells in the lungs and the unwanted tissue which disturbs the heart rhythm. Due to the fear of lengthy surgical procedures, many people undergo minimal invasive surgeries, favoring market growth. In addition, minimal invasion surgeries have benefits such as less pain, shorter hospital stay, and less recovery time.
Furthermore, the growing adoption of technological developments in the manufacturing of ablation devices in the European region is expected to fuel the growth rate of the European market. For example, in 2022, Biosense Webster launched a HelioStar balloon ablation catheter in Europe, which is used for the cardiac electrophysiological mapping of the atria, which helps to provide relief to people suffering from AFib. According to a recent survey, nearly 11 million people in Europe suffer from AFib, further supporting market growth. As a result, the key players are focusing on developing new types of ablation devices, which help provide advanced treatment to patients. Additionally, increasing investments by the European governments, research and development, and reimbursement policies also aid market growth.
On the other end, the lack of availability of treatment in some countries of Europe hinders the growth of the ablation devices market in Europe. In addition, the treatment may damage surrounding tissue in a few people, negatively impacting the market. In addition, the scarcity of skilled professionals and lack of advanced healthcare infrastructure hamper the growth rate of the Europe ablation devices market.
This research report on the Europe ablation devices market has been segmented and sub-segmented into the following categories:
By Technology:
By Application:
By End-use:
By Country:
Geographically, the European region had a substantial share of the global market in 2021 and is expected to witness a promising CAGR during the forecast period owing to the growing number of product approvals and increasing awareness regarding the use of ablation devices among the European population. For instance, FARAPULSE Pulsed Field Ablation was manufactured by FARAPULSE Inc., which received approval from the European Union, and the device is used to treat paroxysmal atrial fibrillation. In addition, the governments of European have conducted several awareness programs around atrial fibrillation, which is a disease caused due to irregular heart rhythm leading to blood clots supporting the spread of information.
The German market is anticipated to hold a considerable share of the European market during the forecast period. The German market is driven by the growing number of hospitals and clinics providing ablation device treatments. In addition, the rising number of clinical trials to develop various ablation devices for various treatments is expected to boost market growth in Germany. Furthermore, the growing number of robotic technologies for ablation treatment to minimize human errors is estimated to promote the market’s growth rate in Germany.
The UK is expected to showcase a notable CAGR during the forecast period. This is because the growing number of reimbursement policies for the treatment and affordable costs associated with the ablation treatment in the UK is propelling the market growth in the UK.
KEY MARKET PLAYERS:
Boston Scientific Corporation, CONMED Corporation, AngioDynamics, AtriCure, Inc, Bausch & Lomb Incorporated, Biotronik SE & Co. KG, Elekta AB, Olympus Corporation, Varian, Medtronic plc, Ethicon, Inc., Abbott Laboratories and Alcon Laboratories are playing a notable role in the European ablation devices market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region